LRMR (larimartx.com) Rega marang bathi mangsa ngarep

Larimar Corp - logo grafis emiten LRMR

Larimar Therapeutics (LRMR) develops innovative therapies for central nervous system disorders. This chart on GURU.Markets shows a P/E ratio of 0.00, while the company minimizes costs by outsourcing drug production and testing. Growth potential is based on the massive unmet demand from patients with Friedreich's ataxia, which promises a rapid capture of the niche.

LRMR - Rasio prakiraan rega marang bathi Larimar Therapeutics Inc ing rentang 04.07.2022 - 15.11.2026

Rincian metrik keuangan lan pasar larimartx.com (LRMR)

- rega saiki lan proyeksi nilai saham:
Kutipan saham Larimar Pharma|LRMR - Konsensus nilai wajar
- indikator valuasi pasar bisnis:
Nilai pasar Larimar Therapeutics, Inc.|LRMR - Nilai Bisnis
- data ekuitas miturut neraca:
Nilai Buku saben Saham Larimar Therapeutics|LRMR - Ekuitas Perusahaan|Rasio Kapitalisasi marang Aset Bersih larimartx.com|LRMR - Total Aset Perusahaan
- rincian struktur utang lan likuiditas bisnis:
Utang marang Ekuitas Larimar Therapeutics|LRMR - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Larimar Corp|LRMR - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Larimar Corp|LRMR - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Larimar Therapeutics|Rasio cepet larimartx.com
- statistik bathi lan rasio pasar:
LRMR - Bathi resik taunan|Bathi mangsa ngarep Larimar Therapeutics|LRMR - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep Larimar Therapeutics|LRMR - Rasio rega marang bathi tumrap wutah|Pangali EV/EBITDA Larimar Pharma|LRMR - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan Larimar Therapeutics|LRMR - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan larimartx.com|LRMR - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Larimar Therapeutics
- data dodolan lan asil:
LRMR - Dodolan perusahaan|Prakiraan volume dodolan Larimar Therapeutics Inc|LRMR - Multiplikator P/S|Rasio rega marang prakiraan pendapatan Larimar Therapeutics
Analisis kabeh metrik perusahaan:LRMR Larimar Pharma
Produk mawa merek Larimar Therapeutics

The metric is calculated as the ratio of the current market share price to the projected earnings per share. This indicator reflects market expectations regarding the business's future earnings. For Larimar Therapeutics (LRMR), whose developments in rare neurological diseases are independent of macroeconomic cycles, this metric becomes a key measure of investment risk. By analyzing the company's forward P/E ratio, an investor assesses the value of future clinical trial successes.

Perusahaan pesaing

Prakiraan rega marang bathi JAZZ (Jazz Pharma)|CYTK (Cytokinetics Corp) - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep PTC Therapeutics PTCT|SRRK: Rasio rega marang bathi mangsa ngarep|Centessa Corp - Pangali Forward P/E|DYN - Pangali Forward P/E|EWTX (Edgewise Therapeutics Inc) - Prakiraan rega marang bathi|Rapport Corp (RAPP) - Pangali Forward P/E|Rega marang bathi mangsa ngarep Alumis Inc.|ZVRA: Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Contineum Corp (CTNM)|CAPR - Rasio prakiraan rega marang bathi|Rega marang bathi mangsa ngarep Entrada TRDA|Channel Pharma - Rega marang bathi mangsa ngarep|MNOV - Rega marang bathi mangsa ngarep|Pangali forward rega marang bathi Serina Therapeutics (SER)|BTAI: Pangali Forward P/E|Rasio prakiraan rega marang bathi ProMIS (PMN)|Prakiraan rega marang bathi APUS|Rasio prakiraan rega marang bathi AEON Biopharma AEON|Rega marang bathi mangsa ngarep NLS Pharma (NLSP)|Rega marang bathi mangsa ngarep BNOX (Bionomics)|Rega marang bathi mangsa ngarep FSD Pharma, Inc. HUGE|Reata Pharmaceuticals, Inc. (RETA) - Rasio prakiraan rega marang bathi